Onyx Biotec
ONYX NSE
Onyx Biotec
HealthcareNSE: ONYX Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹70.26 Cr
Volatility
Moderate
P/E Ratio
-322.9
EBITDA
₹3.40 Cr
Return on Equity
8.91%
Debt to Equity
0.27
Book Value
₹30.56
52W High
₹50
52W Low
₹24.2
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
2- Company has low interest coverage ratio.
- Company has a low return on equity of 6.49% over last 3 years.
Growth Rate
Revenue Growth
10.1% lower than
3Y
Net Income Growth
-116% higher than
3Y
Cash Flow Change
-6.58% higher than
3Y
ROE
-38% lower than
3Y
ROCE
1.02% lower than
3Y
EBITDA Margin (Avg.)
-73.36% lower than
3Y
Quarterly Results
| Particulars | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 23.89 | 29.86 | 30.15 | 31.8 | 34.59 | 34.88 |
| Expenses | 20.47 | 24.95 | 24.44 | 27.17 | 33.65 | 32.43 |
| Operating Profit | 3.42 | 4.91 | 5.71 | 4.63 | 0.94 | 2.45 |
| OPM % | 14.32% | 16.44% | 18.94% | 14.56% | 2.72% | 7.02% |
| Other Income | 0.04 | 0.09 | 0.99 | 0.18 | 0.24 | 0.21 |
| Interest | 0.83 | 1.27 | 1.36 | 0.62 | 0.55 | 0.66 |
| Depreciation | 0.73 | 1.14 | 1.53 | 1.51 | 1.56 | 1.49 |
| PBT | 1.9 | 2.59 | 3.81 | 2.68 | -0.93 | 0.51 |
| Tax % | 15.26% | 21.24% | 21.52% | 26.12% | -3.23% | -35.29% |
| Net Profit | 1.6 | 2.03 | 2.99 | 1.97 | -0.9 | 0.69 |
| EPS in Rs | 2.71 | 1.52 | 2.24 | 1.09 | -0.5 | 0.38 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 44.86 | 39.49 | 53.75 | 61.95 | 69.47 |
| Expenses | 39.09 | 34.99 | 45.36 | 51.57 | 66.07 |
| Operating Profit | 5.77 | 4.5 | 8.39 | 10.38 | 3.4 |
| OPM % | 12.86% | 11.4% | 15.61% | 16.76% | 4.89% |
| Other Income | 0.12 | 0.11 | 0.13 | 1.17 | 0.44 |
| Interest | 0.65 | 0.57 | 2.16 | 2.02 | 1.21 |
| Depreciation | 1.45 | 1.49 | 1.87 | 3.05 | 3.05 |
| PBT | 3.79 | 2.55 | 4.49 | 6.48 | -0.42 |
| Tax % | 11.61% | 27.45% | 19.15% | 23.46% | -50% |
| Net Profit | 3.35 | 1.84 | 3.63 | 4.95 | -0.21 |
| EPS in Rs | 5.68 | 3.12 | 2.72 | 2.73 | -0.12 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 5.9 | 5.9 | 13.32 | 18.13 | 18.13 |
| Reserves | 10.47 | 12.3 | 11.97 | 37.49 | 37.28 |
| Borrowings | 12.25 | 29.23 | 30.78 | 12.46 | 15.17 |
| Other Liabilities | 8.22 | 11.3 | 18.07 | 23.17 | 24.57 |
| Total Liabilities | 36.84 | 58.73 | 74.14 | 91.25 | 95.15 |
| Fixed Assets | 17.23 | 42.5 | 43.48 | 40.9 | 39.16 |
| CWIP | 4.02 | 0 | 0 | 0 | 3.68 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 15.59 | 16.23 | 30.66 | 50.35 | 52.31 |
| Total Assets | 36.84 | 58.73 | 74.14 | 91.25 | 95.15 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 0.49 | 1.96 | 1.52 | 1.42 | -1.49 |
| Investing | -5.78 | -22.68 | -3.15 | 0.66 | -4.58 |
| Financing | 5.2 | 16.43 | 3.09 | 5.07 | 1.5 |
| Net Cash Flow | -0.09 | -4.3 | 1.46 | 7.15 | -4.57 |
| Free Cash Flow | -5.3 | -20.78 | -1.7 | 1.91 | -6.48 |
| CFO/OP | 8 | 44 | 18 | 14 | -44 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 68.51 | 46.95 | 104 | 119 | 144 |
| Inventory Days | 41.98 | 110 | 92.94 | 150 | 99.2 |
| Days Payable | 59.46 | 120 | 141 | 156 | 125 |
| Cash Conversion Cycle | 51.03 | 36.71 | 56.48 | 113 | 119 |
| Working Capital Days | 35.72 | -52.22 | 37.62 | 87.49 | 77.29 |
| ROCE % | — | 8.23% | 12.85% | 12.16% | 1.14% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Onyx Biotec insights
47 extracted metrics + investor summaries across FY22–FY26.
Documents
1
Copy of Newspaper Publication
7 Sep - 21st AGM on September 28, 2026 via VC/OAVM; e-voting details and annual report dispatched. 7 Sep - 21st AGM on September 28, 2026 via VC/OAVM; e-voting details and annual report dispatched.
2
Copy of Newspaper Publication
5 Sep - Onyx Biotec published newspaper notice for 21st AGM on 28 September 2026; e-voting from 25-27 September. 5 Sep - Onyx Biotec published newspaper notice for 21st AGM on 28 September 2026; e-voting from 25-27 September.
3
Shareholders meeting
5 Sep - 21st AGM on September 28, 2026; Naresh Kumar re-designation to Managing Director proposed. 5 Sep - 21st AGM on September 28, 2026; Naresh Kumar re-designation to Managing Director proposed.
4
Outcome of Board Meeting
3 Sep - Board met on 3 Sep 2026; approved 21st AGM on 28 Sep, book closure, and Naresh Kumar as MD. 3 Sep - Board met on 3 Sep 2026; approved 21st AGM on 28 Sep, book closure, and Naresh Kumar as MD.
5
Corrigendum
4 Aug - VC Corporate Advisors Private Limited has Submitted to the Exchange a copy of corrigendum to the public announcement dated July24, 2026 for the attention of … 4 Aug - VC Corporate Advisors Private Limited has Submitted to the Exchange a copy of corrigendum to the public announcement dated July24, 2026 for the attention of …
Frequently Asked Questions about Onyx Biotec
What does Onyx Biotec Ltd do?
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry
Syrup for India and overseas, through a
B2B business model[1]
Where is Onyx Biotec Ltd (ONYX) listed?
Onyx Biotec Ltd trades as ONYX on the NSE.
Which sector does Onyx Biotec Ltd belong to?
Onyx Biotec Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Onyx Biotec Ltd?
Onyx Biotec Ltd has a market capitalisation of ₹70.26 Cr, which places it in the Small Cap band.
What is the PE ratio of Onyx Biotec Ltd?
Onyx Biotec Ltd trades at a PE ratio of -322.90, against a book value of ₹30.56 per share.
What is the 52-week high and low of Onyx Biotec Ltd?
Over the last 52 weeks Onyx Biotec Ltd has traded between ₹24.2 and ₹50.
What is the Return on Equity (ROE) of Onyx Biotec Ltd?
Onyx Biotec Ltd reported a return on equity of 8.91%. Its debt-to-equity ratio is 0.27.
Company Information
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ONYX.md for Onyx Biotec Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.